Iron oxide magnetic nanoparticles (MNPs) can be used in targeted drug delivery systems for localized cancer treatment. MNPs coated with biocompatible polymers are useful for delivering anticancer drugs. Iron oxide MNPs were synthesized via co-precipitation method then coated with either chitosan (CS) or polyethylene glycol (PEG) to form CS-MNPs and PEG-MNPs, respectively. Arginine (Arg) was loaded onto both coated nanoparticles to form Arg-CS-MNP and Arg-PEG-MNP nanocomposites. The X-ray diffraction results for the MNPs and the Arg-CS-MNP and Arg-PEG-MNPs nanocomposites indicated that the iron oxide contained pure magnetite. The amount of CS and PEG bound to the MNPs were estimated via thermogravimetric analysis and confirmed via Fourier transform infrared spectroscopy analysis. Arg loading was estimated using UV-vis measurements, which yielded values of 5.5% and 11% for the Arg-CS-MNP and Arg-PEG-MNP nanocomposites, respectively. The release profile of Arg from the nanocomposites followed a pseudo-second-order kinetic model. The cytotoxic effects of the MNPs, Arg-CS-MNPs, and Arg-PEG-MNPs were evaluated in human cervical carcinoma cells (HeLa), mouse embryonic fibroblast cells (3T3) and breast adenocarcinoma cells (MCF-7). The results indicate that the MNPs, Arg-CS-MNPs, and Arg-PEG-MNPs do not exhibit cytotoxicity toward 3T3 and HeLa cells. However, treatment of the MCF-7 cells with the Arg-CS-MNP and Arg-PEG-MNP nanocomposites reduced the cancer cell viability with IC 50 values of 48.6 and 42.6 mg/mL, respectively, whereas the MNPs and free Arg did not affect the viability of the MCF-7 cells.
Introduction
Iron oxide magnetic nanoparticles (MNPs) have recently attracted considerable attention due to their versatile features such as superparamagnetism, 1 nontoxicity, 2 good biocompatibility, potential for targeted delivery, 3, 4 low production cost, hyperthermia, 5-7 magnetic resonance imaging, 4, 8 and controlled drug release. These properties allow the potential use of MNPs in various nanotechnology applications. MNPs can bind to various biological molecules given their superparamagnetic properties, high specific area, and rich surface functionality; however, they tend to agglomerate during preparation due to the van der Waals forces between the particles. 9 Their surfaces can be coated with layers of organic polymers to minimize this aggregation.
Various methods have been described for preparing MNPs including chemical co-precipitation, mechanical grinding, hydrolyzation, laser ablation, and microemulsions. 10 The chemical co-precipitation method has often been used due to its simplicity and low cost. In addition, this method can produce the desired sizes and shapes by controlling the solution pH, the reaction temperature, the stirring rate, and the solute and surfactant concentrations. 11 A variety of active compounds has been loaded onto the MNPs, including doxorubicin, [12] [13] [14] [15] [16] 5-aminosalicylic acid, 17 insulin, 18 10hydroxycamptothecin, 19 gallic acid, 20 folic acid, 21 kojic acid, 22 streptomycin, 23 and anthranilic acid. 24 Arginine is an a-amino acid with L and D forms. The Lform is one of the 20 most common naturally occurring amino acids. In the body, arginine changes into nitric oxide (NO), 25 a powerful neurotransmitter that helps blood vessels relax and improves circulation. 26 Arginine may improve blood flow in the coronary arteries and exhibits anticancer properties against lymphosarcoma ascites, fibrosarcoma, human lung carcinoma, and human breast adenocarcinoma cells when delivered in saline at concentrations of at least 150 mM. 27 The syntheses of magnetite nanoparticles and those surfaces functionalized with biocompatible CS and PEG polymers are described herein. The synthesized nanoparticles were loaded with arginine, and the resulting nanocomposites characterized via X-ray powder diffraction (XRD), Fourier transform infrared (FTIR) spectrometry, scanning electron microscopy (SEM), and vibrating sample magnetometer (VSM). In addition, this article examines the cytotoxicity of the resulting nanocomposites on three cell lines-mouse embryonic fibroblast cells (3T3), human cervical carcinoma cells (HeLa), and breast adenocarcinoma cells (MCF-7).
Materials and methods Materials
All chemicals were of reagent grade and used without further purification. Ferric chloride hexahydrate FeCl 3 Á6H 2 O (99%) and ferrous chloride tetrahydrate FeCl 2 Á4H 2 O ()99%) were obtained from Merck KGaA (Darmstadt, Germany). Chitosan (low molecular weight, deacetylation 75-85%), polyethylene glycol polymers, and arginine (97% purity) were purchased from Sigma-Aldrich (St Louis, MO). The acetic acid solution (99.8% purity) was purchased from Hamburg Industries Inc. (Hamburg, Germany).
Deionized water was used for all experiments. Mouse embryonic fibroblast cells (3T3), human cervical carcinoma cells (HeLa), and breast adenocarcinoma cells (MCF-7) were obtained from the American Type Culture Collection (USA).
Preparation of iron oxide nanoparticles
The MNPs were prepared via co-precipitation. 28 Typically, 50 mL of a mixed solution was prepared with 0.15 Mol FeCl 2 and 0.3 Mol FeCl 3 . A 10-mL aliquot of 2 M NaOH was quickly added to the mixture under vigorous stirring; then, additional NaOH was added dropwise under stirring until the solution pH reached 10. The solution was sonicated for an additional 60 min at room temperature. Finally, the precipitate was collected via centrifuge separation and washed three times with deionized water.
Preparation of the CS-MNP and PEG-MNP nanoparticles
Surface modification of the MNPs was carried out by treating the nanoparticles with either CS or PEG. The CS solution was prepared by dissolving 0.5 g CS powder in a 1% acetic acid solution. Similarly, the PEG solution was prepared by dissolving 0.5 g of the polymer in 100 mL water. MNPs were combined with the CS and PEG solutions in a flask for each respective preparation. The mixtures were stirred for 18 h. The coated particles-CS-MNPs (chitosan-coated MNPs) and
PEG-MNPs (polyethylene glycol-coated MNPs)-were separated using a permanent magnet and dried at 70 C for 2 h.
Preparation of the Arg-CS-MNP and Arg-PEG-MNP nanocomposites
Arginine was loaded onto the CS-MNPs and PEG-MNPs using a method similar to one described in the literature. 29 A known weight of the CS-MNP or PEG-MNP nanoparticles was added to the Arg solution (5 mg/mL). The CS-MNP and PEG-MNP mixtures in the Arg solution were magnetically stirred at room temperature for 18 h to facilitate arginine uptake. The products-Arg-CS-MNPs (arginine loaded on chitosan-coated MNPs) and Arg-PEG-MNPs (arginine loaded on polyethylene glycol-coated MNPs)-were separated using a permanent magnet.
Arginine quantities loaded and released from Ar-CS-MNP and Arg-PEG-MNP nanocomposites
To measure the quantity of Arg loaded onto the MNPs, 5 mg from each nanocomposite solution was weighed and re-suspended for 24 h in phosphate-buffered saline (PBS) (pH 4.8) to facilitate a complete release of the Arg from the nanocomposites. The Arg concentration was then measured via UV-vis spectrophotometry using the Arg absorbance at 206 nm and calibration curves.
To examine the percentage release and the drug release kinetics, 85 mg of each nanocomposite was suspended in 250 mL PBS buffer at pH 7.4. The release medium (3 mL) was removed for analysis at given time intervals and replaced with 3 mL of the buffered solution. The accumulated quantity of arginine released into the solution was measured at different times using a UV-vis spectrophotometer at 206 nm.
Cell culturing and MTT cytotoxicity assays
The 3T3, HeLa, and MCF-7 cells were grown in Dulbecco's modified Eagle's medium (DMEM) containing 10% fetal bovine serum and 1% antibiotics at 37 C in humidified air with 5% CO 2 .
For the viability study, the cells were seeded onto 96-well plates at a density of 1 Â 10 5 cells/well and incubated overnight at 37 C under a 5% CO 2 atmosphere. The media in the wells were then replaced with fresh media containing MNPs, CS, PEG, Arg, Arg-CS-MNPs, and Arg-PEG-MNPs at concentrations of 1.562, 3.125, 6.25, 12.5, 25, and 50 mg/mL, respectively. After 24 h, the effects of the samples on cell viability were determined using MTT (3-(4,5-dimethylthiazol-2yl)-2,5-diphenyltetrazolium bromide) assays. A 10 -mL aliquot of the MTT solution was added to each well and incubated for 4 h. The supernatants were then removed. Dimethyl sulfoxide (DMSO) was added to each well. The absorbance of the cells was measured at 570 nm using a microplate reader. The cell viability experiments were performed at least three times on different occasions with cells not exposed to any treatment serving as controls in each set of experiments.
Instrumentation
Powder XRD patterns were used to determine the crystal structures of the samples in the range of 25-70 on an XRD-6000 diffractometer (Shimadzu, Tokyo, Japan) using CuK a radiation ( ¼ 1.5406 Å ) at 30 kV and 30 mA. FTIR spectra of the materials were recorded from 400 to 4000 cm À1 on a Thermo Nicolet Nexus, Smart Orbit spectrometer using the KBr disc method. Thermogravimetric analysis was carried out using a Metter-Toledo 851e instrument (Switzerland) with a heating rate of 10 C/min in 150-mL alumina crucibles from 30 to 900 C. A NOVA NanoSEM 230 (FEI, Hillsboro, OR) scanning electron microscope was used to observe the surface morphology of the samples. The magnetic properties were evaluated with a Lakeshose 7404 VSM. A UV-vis spectrophotometer (Perkin Elmer. Waltham, MA) was used determine the optical properties and to perform a controlled-release study. The average diameters of the pure MNPs and the Arg-CS-MNP and Arg-PEG-MNP nanocomposites can be evaluated from the XRD data using the Debye-Scherrer equation, which gives the relationship between XRD peak broadening and the average diameter (equation 1).
Results and discussion

X-ray diffraction
in which D is the average diameter, k is the Sherrer constant (0.89), is the X-ray wavelength (0.15418 nm), is the peak width of the half-maximum intensity, and is the Bragg diffraction angle. This equation yielded average diameters for the MNPs and the Arg-CS-MNP and Arg-PEG-MNP nanocomposites of approximately 11.1, 2.4 and 2.5 nm, respectively. An increase in the particle size was expected after coating the MNPs surfaces with the polymer and loading the MNPs with Arg; however, we observed a slight decrease in particle sizes for the Arg-CS-MNP and Arg-PEG-MNP nanocomposites, which may be attributed to prolonged vigorous stirring at high speeds after the addition of the polymer and the drugs. A similar result was reported by Yu and Chow. 31
Infrared spectroscopy
The FTIR spectra for the MNPs, Arg-CS-MNP, Arg-PEG-MNP, and free Arg are provided in Figure 2 (I). The absorption band at 537 cm À1 in the MNPs spectrum ( Figure 2Ia ) is characteristic of Fe-O-Fe in Fe 3 O 4 , but shifts to 543 and 544 cm À1 for the Arg-CS-MNP and Arg-PEG-MNP, respectively, confirming the presence of magnetite nanoparticles.
The FTIR spectrum of the Arg-CS-MNP nanocomposite exhibits bands characteristic of CS, demonstrating that the magnetite nanoparticles were successfully coated with chitosan ( Figure 2IIb ). For example, a band at approximately 1576 cm À1 was assigned to NH 3 þ . 32 The bands at 1399 and 1127 cm À1 were due to O-H bending of the primary alcohol group and the C-N stretching in chitosan, respectively. 13, 33 The glycosidic bond stretching vibrations of CS appeared at 1028 cm À1 . 19 The FTIR spectrum of the Arg-PEG-MNPs is presented in Figure 2 (IIc). The C-O-C ether stretching band appeared at 1098 cm À1 ; the bands at 2912 and 950 cm À1 were due to the -CH 2 stretching vibrations and the -CH out-of-plane bending vibrations, respectively. 21, 34, 35 The C-O-C, -CH 2 , and -CH bands provide strong evidence that PEG coated the nanoparticle surfaces. In addition, the appearance of Arg bands in the Arg-CS-MNP and Arg-PEG-MNP nanocomposites confirms the loading of Arg onto the CS-MNP and PEG-MNP surfaces. For example, the COOsymmetric and asymmetric stretching modes for Arg in Arg-CS-MNP appear at 1564 and 1399 cm À1 , respectively (Figure 2IIb ). For Arg-PEG-MNP, these stretching modes appear at 1623 and 1399 cm À1 ( Figure 2IIC ). 36 Figure 3 (a) provides schema describing the interactions between the Arg, CS, and MNPs. The CS binds the MNPs through glycosidic bonds. The COO À group of Arg interacts with the protonated amino group (NH 3 þ ) from CS. Figure 3 (b) depicts the interactions in the Arg-PEG-MNP nanocomposite. The PEG molecules attach to the MNPs through hydrogen bonding, and the COO À on Arg interacts with an O-H group on the PEG.
Thermogravimetric analysis
TGA was performed to verify the coating and loading formation on the MNP surfaces. Figure 4 provides the TGA curves for the MNPs, CS-MNP, and PEG-MNP. The initial weight loss of 3.9% occurring in the MNPs up to 210 C may be related to the removal of surface hydroxyl groups and/or adsorbed water. 37 The weight loss increased another 1.9% above 210 C. For the CS-MNPs and PEG-MNPs, a slight weight loss was observed up to 260 C in both curves likely due to the adsorbed water. Significant weight loss was detected between 260 C and 600 C. The weight loss for the CS-MNPs (7.2%) was attributed to the decomposition of the CS coating on the surface (inset curve of Figure 4a ). The 9.4% weight loss for the PEG-MNPs was primarily attributed to the PEG decomposition (inset curve of Figure 4b ). By comparing the weight loss curves of the MNPs with the CS-MNP and PEG-MNP nanocomposites, the quantities of CS and PEG coated onto the MNPs were estimated at 5.3 and 7.5%, respectively. [38] [39] [40] The Arg was loaded onto the surface of the CS-MNPs and PEG-MNPs to form Arg-CS-MNP and Arg-PEG-MNP nanocomposites, respectively. Significant weight loss was noted between 260 C and 600 C. The total weight loss for the Arg-CS-MNPs was 13.2%, which was attributed to the decomposition of CS and Arg, while the loss for the Arg-PEG-MNPs was 18.8%, primarily due to the decomposition of PEG and Arg. Comparing the weight loss curves of the CS-MNPs and PEG-MNPs with the Arg-CS-MNP and Arg-PEG-MNP nanocomposites allowed estimations of the Arg quantities loaded onto the Arg-CS-MNPs and Arg-PEG-MNPs of 6.0% and 9.4%, respectively. These results are consistent with the loads calculated from the UV-vis measurements and the Arg standard calibration curves, which yielded values of 5.5% and 11% for the Arg-CS-MNP and Arg-PEG-MNP nanocomposites, respectively. 41 
Measurement of the magnetic properties
Magnetic nanomaterials with superparamagnetic properties are important as targeted carriers. MNPs smaller than 30 nm exhibit superparamagnetic properties. Therefore, the MNPs, Arg-CS-MNP, and Arg-PEG-MNP samples prepared in this work had superparamagnetic properties as verified by the lack of hysteresis in the magnetization curves measured via VSM (inset in Figure  5 ). 42 The magnetization hysteresis loops of the MNPs, Arg-CS-MNPs, and Arg-PEG-MNPs are provided in Figure 5 Figure 5 indicates that the M s of the MNPs nanoparticles decreased after coating with CS and PEG polymers. The decrease in M s is due to the exchange of electrons between the surface Fe atoms and the CS and PEG polymers 31, 43, 44 and implies successful coating of the CS and PEG on the MNPs.
Scanning electron microscope
The SEM images of the pure MNPs and the Arg-CS-MNP and Arg-PEG-MNP nanocomposites are provided in Figure 6 . The agglomeration of the synthesized MNPs nanoparticles is strong due to the van der Waals forces between the particles. 9 After coating the surface, the agglomeration of the Arg-CS-MNP and Arg-PEG-MNP nanocomposites was reduced, indicating that the coating of the MNPs with CS and PEG increases their circulation time in the blood stream and permeability through body tissues. 45 
Determination of the mean size and size distribution properties
Transmission electron microscopy of the Arg-CS-MNP and Arg-PEG-MNP nanocomposites was performed to determine their shapes and sizes. The particle size and size distribution of the nanocomposites was calculated using image analysis software with at least 100 particles chosen randomly from the nanocomposite samples. Figure 7 indicates that the Arg-CS-MNP and Arg-PEG-MNP nanocomposites are spherical. The nanocomposites were small, 9-14 nm in diameter, with a narrow size distribution. The average size of the Arg-CS-MNP nanocomposites was 11.4 nm (Figure 7a ), and the mean size of the Arg-PEG-MNP nanocomposites was 13.0 nm (Figure 7b ).
In vitro study of arginine release from the nanocomposites Figure 8 provides the release profiles of Arg from the Arg-CS-MNP and Arg-PEG-MNP nanocomposites in PBS (pH 7.4) at room temperature. The two types of nanocomposites exhibited rapid release profiles over 90 min. After incubation in PBS for 150 min, the cumulative quantities of Arg released from the Arg-CS-MNPs and Arg-PEG-MNPs were 77.5% and 97.6%, respectively. The Arg-CS-MNP conjugated nanocomposite exhibited a lower release rate than the Arg-PEG-MNP sample due to the electrostatic interactions between the NH 3 þ groups from CS and the COO À groups from Arg (Figure 3 ). The inset in Figure 7 provides the complete release profiles of arginine from the nanocomposites at pH 4.8. 
Release kinetics of arginine anions from the Arg-CS-MNP and Arg-PEG-MNP nanocomposites
The release profiles of drugs from nanoparticles can generally be described with one of the following kinetics models:
1.The pseudo-first-order kinetic model describes the release from nanocomposites in which the dissolution rate depends on the quantity of drug present in the nanocomposite. The equation may be represented in its linear form as equation (2) 46
in which q e and q t are the quantity released at equilibrium and the quantity released at any time (t), respectively, and k 1 is the rate constant of the pseudo-first-order release kinetics. If pseudo-firstorder kinetics are applicable, a plot of ln(q e À q t ) versus t will be linear, and the k 1 value can be obtained from the slope of the linear plot. 
2.The pseudo-second-order kinetic equation may be
represented in its linear form as equation (3) 47
in which k 2 is the rate constant of the pseudo-secondorder release kinetics. If pseudo-second-order kinetics are applicable, then a plot of t/q t versus t will be linear, allowing for the computation of k 2 . 3.The Higuchi model describes the increased release of the drug from the nanocomposites with the increasing the square root of time 48
in which k H is the Higuchi rate constant. 4.The Hixson-Crowell model gives the relationship between the cube root of the percentage of drug remaining in the nanocomposites as a function of time 48 ffiffiffiffiffiffiffi
in which M o is the initial quantity of drug in the nanocomposite and q t is the quantity released at time t.
5.
The Korsmeyer-Peppas model gives the relationship between the log of percentage of drug released and the log of time 48
in which q 1 is the release at infinite time.
These five kinetics models were tested for the arginine anion release kinetic data, and the pseudo-secondorder model was deemed most satisfactory for describing the release kinetics of arginine anions from CS-MNPs and PEG-MNPs (Figure 9 ). The correlation coefficients (R 2 ) were used as criteria for choosing the best model to describe the drug release from the nanocomposites. The 
Cytotoxicity studies
The effects of the MNPs, Arg, CS, PEG, Arg-CS-MNPs, and Arg-PEG-MNPs on cell viability were assessed via MTT assay in three different cell lines (i.e. normal cells (3T3) and cancer cells (HeLa and MCF-7 cells)) ( Figure 10 ). The MTT assay is a standard colorimetric assay for measuring cell proliferation that depends on the cleavage of the tetrazolium rings in MTT, which has a yellow color but forms a dark blue formazan crystal due to mitochondrial dehydrogenase enzymes in viable cells. These dark blue formazan crystals accumulate within healthy cells. Thus, the number of viable cells is directly proportional to the level of the formazan product. As indicated in Figures 10(a) and (b), the Arg-CS-MNP and Arg-PEG-MNP nanocomposites and the components of these nanocomposites (MNPs, Arg, CS, and PEG) exhibited no cytotoxicity toward the 3T3 and HeLa cells at concentrations up to 50 mg/mL. Upon closer examination, Figure 10 (c) indicates that the Arg-CS-MNP and Arg-PEG-MNP nanocomposites have cancer suppression properties with IC 50 values of 48.6 and 42.6 mg/mL, respectively (the IC 50 can be defined as the half maximal inhibitory concentration); compared with MNPs and free Arg, which exhibit no toxic effects. This result may be due to the small size of the MNPs and the positive zeta potentials of the nanocomposites, which facilitate their entry and the release of the drug into the cells. Free Arg demonstrated a cytotoxic effect toward MCF-7 cells with an IC 50 value of 12.8 mM (2229.8 mg/mL), 27 whereas the Arg was released from the Arg-CS-MNP and Arg-PEG-MNP nanocomposites with IC 50 values of 48.6 and 42.6 mg/mL, respectively. Therefore, delivery by the nanocomposites is 46 times more effective than administration of free Arg.
Conclusion
Iron oxide superparamagnetic particles were prepared via co-precipitation and were subsequently modified with either CS or PEG as confirmed by FTIR. According to their XRD patterns, the iron oxide cores of the MNPs and the Arg-CS-MNP and Arg-PEG-MNP nanocomposites were composed of pure magnetite. Drug loading was confirmed via UV-vis spectrophotometry, and the in vitro release behavior was investigated. Most of the Arg was released from the CS-MNPs and PEG-MNPs into a phosphate buffer (pH 7.4) with release percentages of 77.5% and 97.6%, respectively. The drug release kinetics followed a pseudo-second-order model. The Arg-CS-MNP and Arg-PEG-MNP nanocomposites did not demonstrate any toxic effects on 3T3 and HeLa cells at concentrations up to 50 mg/mL. The Arg-CS-MNP and Arg-PEG-MNP nanocomposites exhibited cancer suppression properties with IC 50 values of 48.6 and 42.6 mg/mL, respectively.
Funding
This work was supported by the Ministry of Higher Education of Malaysia (MOHE) grant no. ERGS/1/11/ STG/UPM/01/18 (vote 5527050).
